Last $108.07 USD
Change Today +1.62 / 1.52%
Volume 8.4M
COV On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:04 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by COVIDIEN PLC (COV) in the last 6 months

Announced 11/2/14
30.00M for Covidien plc, Stellarex DCB platform
Merger/Acquisition

The Spectranetics Corporation (Nasdaq:SPNC) agreed to acquire Stellarex DCB platform from Covidien plc (NYSE:COV) for $30 million in cash on October 31, 2014. In connection with the transaction, Spectranetics and Covidien are entering into a product supply agreement pursuant to which Covidien agrees to supply certain angioplasty balloon catheter products to Spectranetics, subject to the terms and conditions set forth in the agreement. The agreement will have an initial ...
Read More


COV's price was unchanged after the transaction was announced on 11/2/14.
Investor / Buyer
The Spectranetics Corporation
Creditor / Lender
Covidien plc
 
Announced 08/28/14
Sapheon, Inc.
Merger/Acquisition

Covidien plc (NYSE: COV) acquired Sapheon, Inc. from Main Line Equity Partners, LLC and others on August 28, 2014. The transaction will be slightly dilutive to adjusted earnings, and is not expected to be material to results. Diane Holt Frankle of Kaye Scholer LLP and Simon Inman, Adam Rosenblum and Theresa Gatesacted of Carle, Mackie, Power & Ross LLP acted as legal advisor to Sapheon, Inc. Sally A. Thurston of Skadden, Arps, Slate, Meagher & Flom, L.L.P. acted as legal ...
Read More


COV's price was unchanged after the transaction was announced on 08/28/14.
Investor / Buyer
Covidien plc
Creditor / Lender
Main Line Equity Partners, LLC
Financial Advisor
TM Asante Healthcare Partners
Legal Advisor
Carle, Mackie, Power & Ross LLP
Kaye Scholer LLP
 
Announced 08/22/14
Reverse Medical Corporation
Merger/Acquisition

Covidien plc (NYSE:COV) acquired Reverse Medical Corporation from a group of sellers on August 22, 2014. The sellers included BioStar Ventures, Early Stage Partners, LP, Emergent Medical Partners, NBGI Ventures, Terra Rossa Capital Pty Ltd, yet2Ventures and others. Covidien will report the Reverse Medical business as part of its Neurovascular product line in the Medical Devices segment.


COV's price was unchanged after the transaction was announced on 08/22/14.
Investor / Buyer
Covidien plc
Creditor / Lender
BioStar Ventures LLC
Early Stage Partners, LP
Emergent Medical Partners
NBGI Ventures
Terra Rossa Capital Pty Ltd
yet2Ventures
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COV:US $108.07 USD +1.62

COV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COV.
View Industry Companies
 

Industry Analysis

COV

Industry Average

Valuation COV Industry Range
No financial data is available for COV.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COVIDIEN PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.